13D Filing: Ventech Capital II and Eyegate Pharmaceuticals Inc (EYEG)

CUSIP No. 30233M 107

13D

Page 8 of 11

Item 1.    Security and Issuer.

This Amendment No. 1 amends and supplements
the statement on Schedule 13D originally filed by the Reporting Persons (as defined below) with the SEC on March 3, 2015, and
relates to the common stock, $.01 par value (the “Common Stock”) of EyeGate Pharmaceuticals, Inc. (the “Issuer”),
having its principal executive office at 271 Waverley Oaks Road, Suite 108, Waltham, MA 02452. This Amendment No. 1 is being filed
to update the percentage of Common Stock of the Issuer beneficially owned by the Reporting Persons as a result of dilution due
to equity issuances by the Issuer. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information
previously reported on the Schedule 13D. Unless otherwise indicated, each capitalized term used by not defined herein shall have
the meaning assigned to such term in the Schedule 13D.

Item 2.    Identity and Background.

Item 2 is hereby amended and supplemented as follows:

(a)

This statement is being filed by:

(i)

FCPR Ventech A, a Fonds Communs de Placement à Risque, or investment fund;

(ii)

FCPR Ventech B, an investment fund;

(iii)

FCPR Ventech Coinvest, an investment fund;

(iv)

FCPR Ventech Capital II, an investment fund;

(v)

Alain Caffi, as a director of Ventech SA, a French Société Anonyme (corporation) (“Ventech”), with voting and investment power with respect to the foregoing entities; and

(vi)

Jean Bourcereau, as a director of Ventech, with voting and investment power with respect to the foregoing entities.

The persons named in this Item 2(a) are
referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.” The
persons named in Item 2(a)(ii) through Item 2(a)(iv) are referred to individually herein as an “Investment Fund” and
collectively as the “Investment Funds.”

(b)

The address of the principal business office of each Reporting Person is 47, avenue de l’Opéra, Paris, France 75002.

(c)

The principal business of each Investment Fund is to make, hold, and dispose of equity and equity related investments.

(d)

During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding.

(e)

During the five years prior to the date hereof, none of the Reporting Persons has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)

Each of the Investment Funds is a French Fonds Communs de Placement à Risque. Each of Alain Caffi and Jean Bourcereau are French citizens.